6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03301272 (ClinicalTrials.gov)	March 22, 2018	13/9/2017	Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease	Effectiveness of Onabotulinumtoxin A on Reduction of Rest Tremor in Parkinson's Disease: a Pilot Study	Parkinson Disease	Drug: Onabotulinumtoxin A Injection;Other: Placebo	University of North Carolina, Chapel Hill	NULL	Completed	45 Years	80 Years	All	16	Phase 2	United States
2	NCT02472210 (ClinicalTrials.gov)	July 2014	11/6/2015	The Use of Botox in Advanced Parkinson's Patients Experiencing Pain	A Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot Study	Parkinson's Disease	Drug: Botulinum Toxin	University Health Network, Toronto	NULL	Active, not recruiting	18 Years	N/A	Both	14	Phase 4	NULL
3	EUCTR2009-017412-32-IT (EUCTR)	13/12/2011	27/04/2010	RANDOMISED CONTROLLED TRIAL OF BOTULINUM TOXIN TYPE A AND B EFFICACY IN REDUCING DROOLING IN PARKINSON DISEASE - ND	RANDOMISED CONTROLLED TRIAL OF BOTULINUM TOXIN TYPE A AND B EFFICACY IN REDUCING DROOLING IN PARKINSON DISEASE - ND	Parkinson disease MedDRA version: 9.1;Level: LLT;Classification code 10013363	Trade Name: BOTOX INN or Proposed INN: Botulinum toxin Trade Name: NEUROBLOC INN or Proposed INN: Botulinum toxin	AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI	NULL	Not Recruiting			Female: yes Male: yes			Italy
4	NCT01421719 (ClinicalTrials.gov)	February 2009	19/8/2011	Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease	Onabotulinum Toxin Type A (BTX-A) For Treatment of Neurogenic Overactive Bladder Due to Parkinson's Disease: Safety and Efficacy	Parkinson's Disease;Neurogenic Bladder;Urinary Incontinence;Clostridium Botulinum Toxin Adverse Reaction	Drug: Cystoscopic injection of Botox into the urinary bladder	Stanford University	Allergan	Completed	50 Years	85 Years	All	20	Phase 4	United States
5	NCT00477802 (ClinicalTrials.gov)	May 2007	22/5/2007	Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease	Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease: A Double-Blind, Randomized, Placebo Controlled, Cross-Over Design Study	Parkinson Disease	Biological: Botulinum Toxin Type A;Biological: Placebo	University of Cincinnati	Allergan	Terminated	35 Years	75 Years	Both	8	Phase 4	United States